A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...
Shares of GlaxoSmithKline Pharmaceuticals were trading at Rs 1,316.95 per scrip on the BSE, up 1.26 per cent from its previous close. AKT BALBAL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback